Src family kinase

Src family kinases (SFKs) are a group of non-receptor tyrosine kinases that are involved in the regulation of cellular processes such as cell growth, differentiation, migration, and apoptosis. They play a pivotal role in the development and progression of various cancers, making them a significant subject of research in oncology and molecular biology. The family is named after the prototypical member, Src (pronounced "sarc" as it is derived from "sarcoma"), which was the first oncogene ever identified.

Structure and Function

SFKs share a common structure comprising several domains: the SH1 domain (also known as the kinase domain), the SH2 and SH3 domains involved in protein-protein interactions, a unique domain specific to each family member, and a regulatory tail. The SH2 and SH3 domains regulate the kinase activity of the SH1 domain, usually keeping the kinase in an inactive state through intramolecular interactions. Activation of SFKs involves the disruption of these interactions, often through the binding of phosphotyrosine residues in the SH2 domain or proline-rich motifs in the SH3 domain.

Members of the Src Family

The Src family includes several members, such as Src, Fyn, Yes, Lck, Hck, Lyn, and Fgr. Each of these kinases has distinct and overlapping roles in cellular signaling pathways. For example, Lck is predominantly expressed in T cells and is crucial for T cell receptor signaling, while Lyn is involved in B cell receptor signaling.

Role in Cancer

Dysregulation of SFK activity has been implicated in the development and progression of various cancers. Overexpression, increased kinase activity, or mutations that lead to constitutive activation of SFKs can result in enhanced cell proliferation, survival, invasion, and metastasis. Consequently, SFKs have become attractive targets for cancer therapy, and several inhibitors of SFKs are currently under clinical development or have been approved for use in treating certain types of cancer.

SFK Inhibitors

Several small molecule inhibitors targeting SFKs have been developed, including dasatinib, bosutinib, and ponatinib. These inhibitors are designed to bind to the ATP-binding site of the kinase domain, thereby preventing ATP from binding and phosphorylating tyrosine residues on substrate proteins. This inhibition can lead to the suppression of tumor growth and progression.

Research and Clinical Implications

Research on SFKs continues to uncover their complex roles in various cellular processes and diseases. Understanding the precise mechanisms by which SFKs contribute to cancer and other diseases is crucial for the development of targeted therapies. Moreover, the study of SFK inhibitors in clinical trials offers hope for more effective cancer treatments with fewer side effects compared to traditional chemotherapy.

See Also

• Protein kinase
• Tyrosine kinase inhibitor
• Signal transduction
• Oncogene

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian